Kisspeptin: research overview

The short version

Kisspeptin is a family of neuropeptides produced in the hypothalamus — the brain region that orchestrates hormone signaling. When kisspeptin binds its receptor, KISS1R (also called GPR54), it fires up the neurons that release GnRH (gonadotropin-releasing hormone), which in turn triggers the pituitary to put out LH and FSH, and the gonads to produce testosterone or estrogen. In plain terms: kisspeptin is the upstream switch that tells the reproductive hormone system to turn on ^[7].

Here is the honest part. Kisspeptin is investigational — no formulation has been approved by any regulator for any clinical indication as of 2025. The human research is largely Phase 1 and Phase 2: it has been studied in women who have lost their menstrual cycle (hypothalamic amenorrhea) ^[4], as an alternative trigger in IVF protocols ^[3], and most recently in a nasal-spray formulation that avoids needles ^[1]. All of that work is done in supervised research settings with pharmaceutical-grade peptide. Kisspeptin is not a supplement. It is not approved for self-use. This page summarizes the evidence; it is not advice and lists no human dose.

What it is

Kisspeptin is actually a family of signaling peptides all encoded by the KISS1 gene. The gene produces a 145-amino-acid precursor protein that gets cleaved into several shorter bioactive fragments: kisspeptin-54 (also historically called metastin, after its original identification as a metastasis-suppressor), and shorter C-terminal fragments kisspeptin-14, kisspeptin-13, and kisspeptin-10. All isoforms share a conserved RF-amide motif at the C-terminus (Arg-Phe-amide) that is required for binding to KISS1R.

The shortest isoform, kisspeptin-10 (KP-10), has the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 and is the most widely used in research bolus-dosing studies. Kisspeptin-54 is used in longer infusion studies. Neither is an approved drug, and neither is a nutritional supplement — they are investigational research compounds.

How it works

Kisspeptin's receptor, KISS1R (also known as GPR54), is a Gq/11-coupled GPCR — a type of cell-surface receptor that activates a downstream signaling cascade when kisspeptin binds. When KISS1R is activated on hypothalamic GnRH neurons, it triggers phospholipase C (PLC), which generates IP3 (inositol trisphosphate) and releases calcium from intracellular stores. That calcium cascade closes potassium channels and opens non-selective cation channels, depolarizing the GnRH neuron — making it fire ^[6].

The result is a pulse of GnRH released into the portal blood, which reaches the pituitary within seconds and triggers a pulse of LH (and to a lesser degree FSH). The research identified this mechanism at the single-cell level in mouse GnRH neurons: kisspeptin at 100 nM depolarized GnRH neurons by about 6 mV and increased firing rate by ~87%, and the effect was blocked when the PLC-IP3-calcium pathway was interrupted ^[6].

Kisspeptin neurons — particularly those in the arcuate nucleus that co-express neurokinin B and dynorphin (the so-called KNDy neurons) — are thought to be the brain's primary GnRH pulse generator ^[4]. Kisspeptin acts upstream of GnRH: it does not itself supply LH, FSH, testosterone, or estrogen. It tells the brain's own neurons to do that.

What the research shows

The genetic proof: kisspeptin-KISS1R signaling is essential for puberty and reproduction. The strongest evidence for kisspeptin's biological importance comes from a genetic study: families with loss-of-function mutations in GPR54 (KISS1R) developed autosomal-recessive idiopathic hypogonadotropic hypogonadism — they failed to go through puberty, with low LH, FSH, and sex steroids. Mice with the Gpr54 gene knocked out reproduced the same infertile phenotype. This established that the kisspeptin-KISS1R axis is not a luxury but a requirement for reproductive maturation ^[7].

LH stimulation in men. In healthy men, intravenous kisspeptin-10 produced dose-dependent LH stimulation: a 1 µg/kg bolus raised LH from 4.1 to 12.4 IU/L at 30 minutes. A continuous infusion at 1.5 µg/kg/h raised mean LH from 5.2 to 14.1 IU/L and increased LH pulse frequency from 0.7 to 1.0 pulses/hour; a higher 4 µg/kg/h rate raised serum testosterone from 16.6 to 24.0 nmol/L ^[5]. These are research-setting measurements, not treatment protocols.

Restoring pulsatility in hypothalamic amenorrhea. In five women who had lost their periods due to hypothalamic suppression, continuous intravenous kisspeptin-54 restored LH pulsatility in a dose-dependent pattern: LH pulses rose from 1.6 to 5.0 per 8 hours (~3-fold), and pulse secretory mass increased ~6-fold versus vehicle. Importantly, the highest infusion rate produced tachyphylaxis — the response faded during continuous exposure at high dose, demonstrating that the KISS1R desensitizes with sustained stimulation ^[4].

IVF trigger in high-OHSS-risk patients. In a Phase 2 randomized trial of 60 women undergoing IVF who were at high risk of ovarian hyperstimulation syndrome (OHSS), subcutaneous kisspeptin-54 successfully triggered oocyte maturation in 95% of women, with no cases of moderate, severe or critical OHSS at any dose. The 9.6 nmol/kg dose produced the highest live-birth rate (62%), supporting kisspeptin as a safer alternative to the standard trigger agent (hCG) in this high-risk population ^[3].

Non-invasive nasal delivery. A 2025 study demonstrated that intranasal kisspeptin-54 rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L), without adverse events — and the formulation was stable for up to 60 days at 4°C ^[1]. This was the first clinical demonstration of effective non-invasive delivery and expands the potential research applications.

Clinical landscape overview. A 2025 systematic review identified 29 interventional clinical trials of kisspeptin (through February 2023), spanning secondary amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition and lactation. The review noted considerably fewer side effects than comparator treatments. Across all these trials, no kisspeptin product has been approved by any regulator for any indication ^[2].

Reported effects, cautions & safety

The following anecdotal reports are drawn from research forums, longevity communities, and fertility trial participant accounts. They are anecdotal, not clinical evidence — subjective accounts from individuals who have used or been exposed to kisspeptin in research or self-experimentation contexts. They are not studied outcomes, not endorsed, and not a basis for dose or use decisions.

Anecdotal signals: potential benefits reported

• Heightened sexual desire and libido. Some research participants and people self-experimenting describe a noticeable lift in sexual interest and spontaneous arousal in the hours after dosing — consistent, perhaps, with the downstream testosterone stimulus observed in male research participants ^[5]. Real-world reports are sparse because kisspeptin is investigational and not mass-marketed.
• Stronger emotional and romantic response. A handful of anecdotal accounts mention feeling more emotionally engaged or attracted to a partner, mirroring the neuroimaging direction of research. Treated as subjective impression only.
• Improved morning or spontaneous erections (men). Some men in research-use communities report firmer or more frequent spontaneous erections — plausibly downstream of the acute testosterone rises observed in study data ^[5]. Wide individual variability; anecdotal only.
• Return of menstrual cycle (women with missed periods). Women in hypothalamic-amenorrhea research settings have described renewed cycle activity, consistent with the published restoration of LH pulsatility ^[4]. Individual-level reports; not a self-treatment outcome.
• General sense of well-being or "switched on" feeling. A minority describe feeling subtly better in the days after use. One controlled study found no significant change in measured anxiety, which suggests that if this signal exists, it is mild and subjective.

Anecdotal signals: adverse effects and limitations reported

• Effect fades with repeated or continuous use (tachyphylaxis). This is the most consistent and clinically validated cautionary signal. Research participants and self-experimenters alike report that a strong first response weakens with frequent exposure — matching the documented KISS1R desensitization ^[4]. The receptor resets, but dense continuous use defeats itself.
• Facial flushing and warmth. Described as transient and anecdotal; plausibly tied to kisspeptin's vascular activity and KNDy-neuron actions.
• Injection-site redness, soreness. As with most injected research peptides, some report local stinging or a small bump; generally described as minor and short-lived.
• Nausea or lightheadedness. Occasional reports; inconsistent between individuals and not a documented common finding in the clinical trials.
• Headache. A minority mention a transient headache after dosing; anecdotal and without a clear pattern.
• Felt nothing / no perceptible effect. Many accounts report no noticeable subjective effect — a common and honest counterpoint. Hormonal changes on lab tests do not always translate into anything a person feels.
• Product identity and quality uncertainty. Research-grade kisspeptin material carries no quality guarantee: correct isoform (KP-10 vs KP-54), accurate sequence, concentration, and sterility are all unverified outside formal pharmaceutical-grade study conditions.

Safety cautions from the literature:

• Investigational and unapproved. No kisspeptin product is approved for any indication; all clinical data come from supervised research settings with pharmaceutical-grade peptide ^[2].
• KISS1R desensitization. Sustained frequent KISS1R activation downregulates the receptor. Even within a single infusion, the highest continuous rate produced tachyphylaxis ^[4]. Continuous exposure is pharmacologically self-defeating.
• Acts on the master reproductive switch. Kisspeptin sits upstream of GnRH and drives the entire HPG axis. Its impact on people with hormone-sensitive conditions, hormonal disorders, or those on hormonal therapy is not established and is theoretically significant ^[7].
• Pregnancy: avoid. Kisspeptin is produced in large amounts by the placenta and directly stimulates reproductive hormone signaling. The effect of exogenous kisspeptin in pregnancy is uncharacterized ^[2].
• Possible vascular activity. In a mouse atherosclerosis model, kisspeptin-10 accelerated plaque progression via GPR54 — a signal reversed by a GPR54 antagonist. No cardiovascular harm has been reported in human studies, but this rodent finding is a reason for caution in anyone with cardiovascular disease ^[5].
• Human safety data are short-term. Controlled studies report acute exposures with no significant changes in blood pressure, heart rate, or anxiety in the sessions studied. Long-term or repeated-exposure safety data do not exist ^[1].

Where it fits in reproductive research

Kisspeptin occupies a unique place on this desk and in endocrinology: it is not a hormone supplement in the conventional sense. It does not supply LH, FSH, testosterone, or estrogen. It activates the body's own hormone-producing neurons ^[6][7]. That makes it interesting for conditions where the axis is suppressed but intact — hypothalamic amenorrhea is the clearest example — and as a research tool for understanding how the reproductive pulse generator works.

On the sexual-health side, the connection to libido is plausible through downstream testosterone and estrogen effects, but the evidence for kisspeptin as a direct desire-modulating compound is indirect — inferred from community anecdote rather than studied head-on. That contrasts with PT-141, which has a direct Phase 3 trial record in sexual desire. Compare these peptides to see how the evidence base, regulatory status, and mechanism differ.